SAB Biotherapeutics Inc (SABS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.18+1.92%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · SABS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -27.4% |
| Our one-year growth estimate | diamond | -96.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 69.5 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
SABS — litigation filed
Dated 2026-07-07
Regulation FD Disclosure. On July 7, 2026, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company” or “SAB BIO”) issued a press release with Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, announcing that Breakthrough T1D, has awarded a grant to Michael J. Haller, M.D., Professor and Chief of Pediatric Endocrinology at the University of Florida in support of PRISE-hATG, a clinical study evaluating SAB-142 in patients with Stage 3 T1D who…
Why it matters: SAB BIO reports ongoing losses and no revenue in the inputs. Its cash update can show whether it can keep funding its trials.
Worry ifThe Nov. 13 report shows a larger quarterly operating loss than Q2 2026’s $23.4 million, or less cash than the prior report.
Less concerning ifThe Nov. 13 report shows a smaller operating loss than $23.4 million and cash that is stable or higher.
Why it matters: This Phase 2b trial is SAB-142’s main test in newly diagnosed patients. Finishing enrollment keeps the stated path to 2027 results on track.
Supportive ifThe company reports that SAFEGUARD enrollment is complete by the end of Q4 2026.
Worry ifThe company says enrollment remains open after Q4 2026 or gives a later end date.
Why it matters: The results will test whether SAB-142 can preserve beta cell function in new-onset Stage 3 T1D. The Phase 1 report had only four treated patients with T1D.
Watch forThe company reports Phase 2b topline results in 2H 2027. The main study measures show a benefit over placebo.
Also watch forThe study misses its main measures or shows no benefit over placebo. The topline readout moves past 2H 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$201 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $583 loss on $10,000 · 5.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,575 loss on $10,000 · 45.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.